Details for New Drug Application (NDA): 022224
The generic ingredient in TRILIPIX is choline fenofibrate. There is one drug master file entry for this compound. Six suppliers are listed for this compound. Additional details are available on the choline fenofibrate profile page.
Summary for 022224
| Tradename: | TRILIPIX |
| Applicant: | Abbvie |
| Ingredient: | choline fenofibrate |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE, DELAYED RELEASE;ORAL | Strength | EQ 45MG FENOFIBRIC ACID **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Dec 15, 2008 | TE: | RLD: | Yes | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE, DELAYED RELEASE;ORAL | Strength | EQ 135MG FENOFIBRIC ACID **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Dec 15, 2008 | TE: | RLD: | Yes | |||||
Expired US Patents for NDA 022224
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Abbvie | TRILIPIX | choline fenofibrate | CAPSULE, DELAYED RELEASE;ORAL | 022224-001 | Dec 15, 2008 | 7,259,186 | ⤷ Start Trial |
| Abbvie | TRILIPIX | choline fenofibrate | CAPSULE, DELAYED RELEASE;ORAL | 022224-002 | Dec 15, 2008 | 7,259,186 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
